Updated: Dec 20, 2023
Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation in diabetes. He reviews Biomea's latest clinical data, and highlights the company's cancer programs.
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
.png){kind=logo}
